Thermo Fisher Completes Tender Offer for Dionex | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific announced today that it has completed its tender offer for Dionex and expects to complete its purchase of the chromatography firm through a short-form merger later this week.

As of the expiration of the offer last Friday and based on preliminary information, more than 16 million shares were tendered and not withdrawn in the tender offer, representing 93 percent of Dionex's issued and outstanding shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.